Curious about today's AI digest?ai-tldr.dev

Daily Digest

Pomegra Startups

IntelliProve Raises €2.7M Seed for Camera Vital Signs

IntelliProve (Ghent) raised a €2.7M seed led by Miles Ahead, for camera-based vital-sign monitoring software.

FundingHealthcareNOTABLE4 min read
IntelliProve Raises €2.7M Seed for Camera Vital Signs

Ghent-based IntelliProve raised a €2.7M seed led by Miles Ahead to certify and scale its 30-second face-scan vital-sign software, including for robots.

Key Takeaways

  • IntelliProve closed a €2.7M seed led by Miles Ahead; the valuation was not disclosed.
  • Funds split roughly into thirds: regulatory work, research, and commercial growth including robotics.
  • Total disclosed funding now stands at about €4.95M across three seed rounds since 2022.

Lead

IntelliProve, a Ghent software company founded in 2021, announced a €2.7M seed round on November 18-19, 2026, led by Belgian early-stage fund Miles Ahead. Wit-Gele Kruis, a Belgian home-nursing organisation, the imec.istart Fund and a group of business angels also participated. The company did not disclose a valuation or the size of each investor's cheque.

The company sells software that reads vital signs from ordinary camera video, with no wearable or blood-pressure cuff. Co-CEO Joeri Tulkens said the money will fund what he called a health sensing layer that care providers can rely on.

What Does IntelliProve Actually Sell?

IntelliProve sells a software layer that measures vital signs from a 30-second face scan using remote photoplethysmography (rPPG), which detects small skin-colour changes caused by blood flow. It reports heart rate, heart rate variability, respiratory rate, systolic and diastolic blood pressure, and resonant breathing, six biomarkers in all.

The product is embedded in other companies' apps rather than sold to consumers directly. Customers are virtual care providers, health insurers and wellness platforms in more than 50 countries. Its three proprietary techniques, named VitalMesh, PulseShape and TripleGate, are meant to hold accuracy across lighting conditions, camera types and movement.

The company says its models are validated on more than 6 million data points and that 97.6% of heart rate readings land within 5 beats per minute of a reference device. That figure is the company's own. Independent clinical validation is what the new money is partly meant to buy.

How Will the €2.7M Be Spent?

Roughly one-third goes to regulatory work, one-third to research and one-third to commercial growth, according to Tulkens. The regulatory third matters most. IntelliProve holds a CE mark as a Class I medical device under the EU Medical Device Regulation and is working toward Class IIa, the tier that generally carries more weight with clinicians and reimbursement bodies.

The research budget targets dataset gaps: additional skin tones, ages, lighting conditions and camera hardware. Skin tone is a known weak point for optical sensing, so broader data is a precondition for the international certification the company wants beyond Europe.

Why Is a Camera Startup Talking About Humanoid Robots?

IntelliProve is pitching its software as a sensing component for humanoid robots in homes and care facilities, alongside smart glasses and self-service kiosks. It says it is working with robotics partners that it has not named. No deployment dates, contract values or pilot results were disclosed.

The logic is simple enough: a robot already carries a camera, and a camera that can read a pulse turns a robot into a monitoring device. Whether care operators will pay for that, and whether regulators will accept a robot-mounted reading as a medical measurement, remains untested. For now the robotics angle is a stated direction, not a revenue line.

What Does This Round Say About the Last One?

The round is larger than both previous seeds combined. IntelliProve raised €1M in November 2022 and €1.25M in January 2025, the latter also led by Miles Ahead. The €2.7M cheque from the same lead suggests the existing investor saw enough in the customer base and regulatory path to size up, and the roughly 22-month gap between rounds points to slow, certification-bound progress rather than fast scaling.

Still, the sums are small against competitors. Israeli rival Binah.ai raised a $13.5M Series B in 2020, and Canadian digital health company Hilo extended its Series B by $19M in 2026. A third disclosed seed, now at roughly €4.95M in total, is a thin war chest for a company seeking Class IIa certification, a multi-region expansion and a robotics push at once. Miles Ahead, which manages about €30M, has now put capital into the company twice.

What Comes Next for Camera-Based Vital Signs?

The next test is regulatory. A Class IIa clearance would let IntelliProve move from wellness-adjacent use cases toward clinical workflows, where insurers and care networks pay more but demand stronger evidence. A delay would leave it competing on price and integration speed against rivals such as YOU(th) Health Tech, which raised $4.5M in 2026, and smedo, which raised a €1.66M seed in 2022.

The wider market gives tailwinds, with remote patient monitoring forecast to grow from $26B in 2025 to $110.7B by 2033, a 20% compound annual rate. Forecasts like that tend to flatter every company in the category, so the more useful signal will be whether IntelliProve names its robotics partners and publishes independent validation within the next two funding cycles.

Outlook

IntelliProve enters 2027 with fresh seed capital, a Class I CE mark, a customer base across 50-plus countries and an unfinished path to Class IIa. Its robotics ambitions are unproven and its accuracy claims await outside verification. A Series A, if it comes, will likely hinge on certification progress and named partners rather than on scan volume.

More Startup News